CR20250476A - Nuevos derivados de amina heterocíclica y composiciones farmacéuticas que comprenden los mismos - Google Patents

Nuevos derivados de amina heterocíclica y composiciones farmacéuticas que comprenden los mismos

Info

Publication number
CR20250476A
CR20250476A CR20250476A CR20250476A CR20250476A CR 20250476 A CR20250476 A CR 20250476A CR 20250476 A CR20250476 A CR 20250476A CR 20250476 A CR20250476 A CR 20250476A CR 20250476 A CR20250476 A CR 20250476A
Authority
CR
Costa Rica
Prior art keywords
same
heterocyclic amine
pharmaceutical compositions
amine derivatives
new heterocyclic
Prior art date
Application number
CR20250476A
Other languages
English (en)
Inventor
Hyeim Jo
Sooyeon Jung
Eunhye Lee
Ahreum Lee
Joon Seok Park
Doohyun Lee
Choongmin Lee
Jaehun Jeong
Hyae Jung Hyun
Original Assignee
Daewoong Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daewoong Pharmaceutical Co Ltd filed Critical Daewoong Pharmaceutical Co Ltd
Publication of CR20250476A publication Critical patent/CR20250476A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente divulgación se refiere a un nuevo derivado de amina heterocíclica representado por la siguiente Fórmula Química 1 o una composición farmacéutica que comprende el mismo. El compuesto de acuerdo con la presente divulgación puede usarse eficazmente para la prevención o el tratamiento de enfermedades inflamatorias, enfermedades autoinmunes o cánceres. [Fórmula Química 1] en la Fórmula Química 1, Y1, R1, A, R2, k, Y2, L, X y R3 son como se definen en la descripción detallada.
CR20250476A 2023-05-04 2024-05-03 Nuevos derivados de amina heterocíclica y composiciones farmacéuticas que comprenden los mismos CR20250476A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20230058527 2023-05-04
PCT/KR2024/006004 WO2024228580A1 (ko) 2023-05-04 2024-05-03 신규한 헤테로사이클릭아민 유도체 및 이를 포함하는 약학 조성물

Publications (1)

Publication Number Publication Date
CR20250476A true CR20250476A (es) 2026-01-19

Family

ID=93333113

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20250476A CR20250476A (es) 2023-05-04 2024-05-03 Nuevos derivados de amina heterocíclica y composiciones farmacéuticas que comprenden los mismos

Country Status (15)

Country Link
EP (1) EP4707277A1 (es)
KR (1) KR102865840B1 (es)
CN (1) CN121002017A (es)
AR (1) AR132607A1 (es)
AU (1) AU2024266528A1 (es)
CL (1) CL2025003350A1 (es)
CO (1) CO2025013436A2 (es)
CR (1) CR20250476A (es)
DO (1) DOP2025000261A (es)
IL (1) IL323670A (es)
JO (1) JOP20250274A1 (es)
MX (1) MX2025012182A (es)
PE (1) PE20252786A1 (es)
TW (1) TWI908054B (es)
WO (1) WO2024228580A1 (es)

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002050071A1 (en) 2000-12-21 2002-06-27 Bristol-Myers Squibb Company Thiazolyl inhibitors of tec family tyrosine kinases
WO2005056785A2 (en) 2003-12-05 2005-06-23 Vertex Pharmaceuticals, Inc. Crystal structure of interleukin-2 tyrosine kinase (itk) and binding pockets thereof
US20070032403A1 (en) 2003-12-30 2007-02-08 Boehringer Ingelheim Pharmaceuticals, Inc. Crystal structure of the ITK kinase domain
AU2006244195B2 (en) * 2005-05-05 2012-03-15 Ardea Biosciences, Inc. Diaryl-purine, azapurines and -deazapurines as non-nucleoside reverse transcriptase inhibitors for treatment of HIV
DK2526933T3 (en) 2006-09-22 2015-05-18 Pharmacyclics Inc Inhibitors of Bruton's tyrosine kinase
EP3170825B1 (en) * 2012-08-06 2019-04-10 ACEA Biosciences Inc. Novel pyrrolopyrimidine compounds as inhibitors of protein kinases
US9573958B2 (en) 2012-08-31 2017-02-21 Principia Biopharma, Inc. Benzimidazole derivatives as ITK inhibitors
CA2887465A1 (en) 2012-10-04 2014-04-10 University Of Utah Research Foundation Substituted n-(3-(pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase btk inhibitors
BR112016008632A8 (pt) 2013-10-21 2020-03-17 Merck Patent Gmbh compostos de heteroarila como inibidores de btk, seus usos, e composição farmacêutica
US10562902B2 (en) * 2015-08-13 2020-02-18 Beijing Hanmi Pharmaceutical Co., Ltd. IRAK4 inhibitor and use thereof
MX388591B (es) * 2016-06-30 2025-03-20 Daewoong Pharmaceutical Co Ltd Derivados de pirazolopirimidina como inhibidor de cinasa.
KR20190043437A (ko) * 2017-10-18 2019-04-26 씨제이헬스케어 주식회사 단백질 키나제 억제제로서의 헤테로고리 화합물
WO2021147953A1 (zh) * 2020-01-21 2021-07-29 江苏先声药业有限公司 嘧啶并五元环类衍生物及其应用
CN115023428B (zh) * 2020-01-21 2025-04-08 江苏先声药业有限公司 嘧啶并吡咯类化合物
CN113845531B (zh) * 2020-06-28 2025-06-27 四川科伦博泰生物医药股份有限公司 吡唑并环类化合物、包含其的药物组合物、其制备方法及其用途
KR20240075952A (ko) * 2021-09-23 2024-05-30 3에이치 파머슈티컬즈 컴퍼니 리미티드 Fgfr 억제제 및 이의 사용 방법

Also Published As

Publication number Publication date
JOP20250274A1 (ar) 2025-10-30
TWI908054B (zh) 2025-12-11
CL2025003350A1 (es) 2026-02-13
KR102865840B1 (ko) 2025-09-29
KR20240161599A (ko) 2024-11-12
AU2024266528A1 (en) 2025-10-16
TW202448453A (zh) 2024-12-16
AR132607A1 (es) 2025-07-16
WO2024228580A1 (ko) 2024-11-07
IL323670A (en) 2025-11-01
DOP2025000261A (es) 2025-11-16
CN121002017A (zh) 2025-11-21
MX2025012182A (es) 2025-11-03
CO2025013436A2 (es) 2025-10-20
PE20252786A1 (es) 2025-12-22
EP4707277A1 (en) 2026-03-11

Similar Documents

Publication Publication Date Title
MX2023012054A (es) Inhibidor derivado heterociclico y metodo de preparacion y su aplicacion.
UY30499A1 (es) Derivados de amina utiles como agentes anticancerigenos
CL2024001106A1 (es) Compuestos heteroarilo bicíclicos fusionados útiles como inhibidores de nlrp3
JO2962B1 (en) Aminopronic derivatives substituted as niprilicin inhibitors
CO6270285A2 (es) Derivados de 4-[(4-amino-1, 3, 5-triazin-2-il)amino]-n-arilmetilcicloalquilcarboxamida
CR11683A (es) Piridinas y pirazinas como inhibidores de p13k
PE20151981A1 (es) Pontenciador de inhibidores del homologo de zeste
UY30206A1 (es) Derivados de diamina, composiciones farmacéuticas conteniéndolos, procesos de preparacion y aplicaciones
PE20121526A1 (es) Compuestos policiclicos heterociclicos como inhibidores del virus de la hepatitis c
CL2021000421A1 (es) Nuevo derivado de amina heterocíclico y composición farmacéutica que lo comprende.
CO2019011604A2 (es) Compuestos inhibidores de vmat2, composiciones y métodos relativos a los mismos
CR11208A (es) Derivados de pirimidina utiles para el tratamiento de condiciones inflamatorias o alergicas
BRPI0817223B8 (pt) inibidores da interação entre mdm2 e p53, seu processo de preparação e seu uso, composição farmacêutica que os compreende e combinação
CL2025001372A1 (es) Derivados de triazinona como inhibidores de nlrp3.
PA8573501A1 (es) Derivados de benzoxazina y su empleo
UY30363A1 (es) Derivados sustituidos de la n-(3-oxo-2,3-dihidro-1h-isoindol-4-il)-1-naftamida, procesos de preparacion, composiciones farmacéuticas y aplicaciones
MX2024011130A (es) Inhibidor de derivados heterociclicos que contienen nitrogeno, metodo de preparacion y utilizacion del mismo
CL2024001481A1 (es) Compuestos de heteroaril-urea novedosos como inhibidores de kv7.2
PA8589801A1 (es) Aminoalcoxiindoles
PH12014501181A1 (en) N- (4 -quinolinylmethyl) sulfonamide derivatives and their use as anthelmintics
BRPI0713951B8 (pt) derivados de quinazolina, e composição farmacêutica
UY30673A1 (es) Derivados 6, 7 y 8 sustituidos del acido (3r)-5-oxo-2,3-dihidro-5h-tiazolo[3,2a]piridin-3-carboxilico, composiciones farmacéuticas conteniéndolos y aplicaciones.
BRPI0507076B8 (pt) quinolinas substituídas, seu processo de preparação, composição farmacêutica que as compreende e seu uso como inibidores micobacterianos
MX2011008677A (es) Derivados de pirazolopirimidina triciclicos.
CR20250476A (es) Nuevos derivados de amina heterocíclica y composiciones farmacéuticas que comprenden los mismos